Angie You

CIK: 0001647664

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ATTO

Attovia Therapeutics, Inc.

Director

ORIC

Oric Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

ATTO
Attovia Therapeutics, Inc.
Aug 4, 2026
Award(A)
Stock Option (Right to Buy)
Direct
27K shares-
ORIC
Oric Pharmaceuticals, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
40K shares-
ORIC
Oric Pharmaceuticals, Inc.
Jun 23, 2025
Purchase(P)
Direct
1.4K shares at avg. $9.43$13K
ORIC
Oric Pharmaceuticals, Inc.
Jun 20, 2025
Purchase(P)
Direct
26.6K shares at avg. $9.39$250K
ORIC
Oric Pharmaceuticals, Inc.
Jan 2, 2025
Award(A)
Stock Option (right to buy)
Direct
35K shares-

		Type	Shares	Price		Ownership
Aug 4, 2026	ATTO Attovia Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	27,000	-	-	Direct
Jan 2, 2026	ORIC Oric Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	40,000	-	-	Direct
Jun 23, 2025	ORIC Oric Pharmaceuticals, Inc.	Purchase(P)	1,403	$9.43	$13,230	Direct
Jun 20, 2025	ORIC Oric Pharmaceuticals, Inc.	Purchase(P)	26,597	$9.39	$249,669	Direct
Jan 2, 2025	ORIC Oric Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct

1-5 of 5 transactions

About You Angie

You Angie (SEC CIK 0001647664) files insider reports with the SEC as Director of Attovia Therapeutics, Inc. (ATTO) and Director of Oric Pharmaceuticals, Inc. (ORIC).

Signal8 holds 5 ownership filings by You Angie (1 Form 3, 4 Form 4), filed between Jan 6, 2025 and Aug 6, 2026. Those filings report 5 transactions, from Jan 2, 2025 to Aug 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on You Angie's filings is in SAN CARLOS, CA.

Recent filings by You Angie

Aug 4, 2026: Grant or award of ATTO derivative securities (Form 4, code A).
Jan 2, 2026: Grant or award of ORIC derivative securities (Form 4, code A).
Jun 23, 2025: Open-market purchase of ORIC shares (Form 4, code P).
Jun 20, 2025: Open-market purchase of ORIC shares (Form 4, code P).
Jan 2, 2025: Grant or award of ORIC derivative securities (Form 4, code A).

Other insiders filing for Attovia Therapeutics, Inc. (ATTO)

Fu Tao, President and CEO
Chan Steven, Chief Financial Officer
WALSH COLIN, Director
GOLDMAN SACHS GROUP INC, Officer
Deep Track Biotechnology Master Fund, Ltd., 10% Owner
venBio Global Strategic Fund IV, L.P., 10% Owner

How to read Form 4 transaction codes